Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk ...

Baseline ctDNA negativity or on-treatment clearance in anal squamous cell carcinoma correlated with 100% one-year overall survival and no local recurrence, whereas post-treatment positivity predicted ...

Among patients who had undergone curative surgery for primary colorectal cancer, the screening methods of computed tomography and carcinoembryonic antigen each provided an improved rate of surgical ...

Pancreatic and colorectal cancers are two of the most concerning cancers. Both are notoriously difficult to detect in their early stages, primarily due to the lack of specific early symptoms and their ...

Low-dose aspirin may slash colorectal cancer recurrence risk by 55%, according to a recent trial. Image credit: soleg/Getty Images The National Cancer Institute predicts that colorectal cancers will ...

While the overall incidence of colorectal cancer has declined, a concerning and divergent trend has emerged: a steady increase in both the incidence and mortality of early-onset rectal cancer in ...

Berberine significantly reduced adenoma recurrence and colorectal neoplasm occurrence in a 6-year follow-up study of nearly 800 patients post-polypectomy. The study found that berberine's ...

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.